Summit Therapeutics (SUMM)

 

Latest News

Summit Therapeutics plc : Holding(s) in Company

Summit Therapeutics plc: Holding(s) in Company TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Summit Therapeutics plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisi...

Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMD

Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMD Summit Therapeutics plc ("Summit" or "the Company") SUMMIT RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM US FDA FOR EZUTROMID IN TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 27 September 2...

Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD

Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD Summit Therapeutics plc ("Summit" or "the Company") SUMMIT RECEIVES FAST TRACK DESIGNATION FROM US FDA FOR EZUTROMID IN THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 26 September 2016 - Summit Ther...

Summit Therapeutics widens H1 loss

Summit Therapeutics has posted an H1 loss of $17.9m, from a loss of $13.5m a year ago. Most of the losses were due to resear...

All News

DateHeadlineSource
28-09-16Summit Therapeutics plc : Holding(s) in CompanyRNS
27-09-16Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMDRNS
26-09-16Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMDRNS
08-09-16Summit Therapeutics widens H1 lossStockMarketWire
08-09-16Summit Therapeutics plc : Half-yearly reportRNS
07-09-16Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment ConferenceRNS
05-09-16Summit Therapeutics plc : Notice of ResultsRNS
09-08-16Summit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate EzutromidRNS
05-08-16Summit Therapeutics to Present at Canaccord Genuity Growth ConferenceRNS
18-07-16Summit Therapeutics plc : Result of AGMRNS
28-06-16Summit Therapeutics plc : Exercise of OptionsRNS
24-06-16Summit Therapeutics plc : Award of OptionsRNS
21-06-16Summit's Ridinilazole Preserves Microbiome During Treatment of C. Difficile InfectionRNS
17-06-16Summit Therapeutics plc : Notice of AGMRNS
17-06-16First Patient Enrolled in Summit's PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMDRNS
16-06-16Summit Therapeutics to Present at JMP Securities Life Sciences ConferenceRNS
08-06-16Summit Therapeutics to Host Utrophin R&D Day 15 June 2016RNS
02-06-16Summit Therapeutics plc : 1st Quarter ResultsRNS
31-05-16Summit Therapeutics plc : Notice of ResultsRNS
23-05-16Summit to Present Phase 2 CoDIFy Trial Data at ASM Microbe 2016RNS
12-05-16Summit Therapeutics File US Annual Report on Form 20-FRNS
10-05-16Summit's FY net losses widenStockMarketWire
10-05-16Summit Therapeutics Reports Financial Results for Q4 and Fiscal Year Ended 31 January 2016RNS
06-05-16Summit Therapeutics plc : Notice of ResultsRNS
28-04-16Summit granted further US patent for ridinilazoleStockMarketWire
28-04-16Summit Announces Further US Patent Granted for CDI Antibiotic RidinilazoleRNS
26-04-16Summit's IND cleared by FDAStockMarketWire
26-04-16Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of EzutromidRNS
14-04-16Summit Therapeutics plc : Exercise of WarrantsRNS
11-04-16Summit sets out findings from P2 CoDIFy trialStockMarketWire
11-04-16Positive Results from Summit's Phase 2 CoDIFy Trial Presented at 26th ECCMID ConferenceRNS
11-04-16Summit Therapeutics plc : Holding(s) in CompanyRNS
06-04-16Summit CEO to present at healthcare conferenceStockMarketWire
06-04-16Summit Therapeutics to Present at 15th Annual Needham Healthcare ConferenceRNS
30-03-16Summit confirms positive P1 trial data for SMT C1100StockMarketWire
30-03-16Summit Reports Positive Interim Data from Phase 1 Testing a New Formulation of SMT C1100 in DMD PatientsRNS
29-03-16Summit to present additional data at conference StockMarketWire
29-03-16SUMMIT TO PRESENT ADDITIONAL DATA FROM PHASE 2 CoDIFy TRIAL FOR THE TREATMENT OF C. DIFFICILE INFECTIONRNS
22-03-16Summit Therapeutics plc : Shareholder NotificationsRNS
15-03-16Summit Announces Publication on Biomarkers to Quantify Utrophin and Regeneration of Muscle Fibres in DMDRNS

RSS feeds

  • Editorial news feed for LSE:SUMM Editorial
  • Regulatory news feed for LSE:SUMM Regulatory